Granulocyte colony–stimulating factor in patients with acute ischemic stroke: results of the AX200 for ischemic stroke trial
EB Ringelstein, V Thijs, B Norrving, A Chamorro… - Stroke, 2013 - Am Heart Assoc
Background and Purpose—Granulocyte colony–stimulating factor (G-CSF; AX200;
Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy. A …
Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy. A …
Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial
EB Ringelstein, V Thijs, B Norrving, A Chamorro… - 2013 - repository.escholarship.umassmed …
BACKGROUND AND PURPOSE: Granulocyte colony-stimulating factor (G-CSF; AX200;
Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy. A …
Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy. A …
[引用][C] Granulocyte Colony―Stimulating Factor in Patients With Acute Ischemic Stroke: Results of the AX200 for Ischemic Stroke Trial
EB RINGELSTEIN, V THIJS, G VOGT… - Stroke …, 2013 - pascal-francis.inist.fr
Granulocyte Colony―Stimulating Factor in Patients With Acute Ischemic Stroke: Results of
the AX200 for Ischemic Stroke Trial CNRS Inist Pascal-Francis CNRS Pascal and Francis …
the AX200 for Ischemic Stroke Trial CNRS Inist Pascal-Francis CNRS Pascal and Francis …
Granulocyte Colony–Stimulating Factor in Patients With Acute Ischemic Stroke
EB Ringelstein, V Thijs, B Norrving, A Chamorro… - Stroke, 2013 - cir.nii.ac.jp
< jats: sec>< jats: title> Background and Purpose—</jats: title>< jats: p> Granulocyte colony–
stimulating factor (G-CSF; AX200; Filgrastim) is a stroke drug candidate with excellent …
stimulating factor (G-CSF; AX200; Filgrastim) is a stroke drug candidate with excellent …
Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial
EB Ringelstein, V Thijs, B Norrving, A Chamorro… - Stroke, 2013 - pubmed.ncbi.nlm.nih.gov
Background and purpose Granulocyte colony-stimulating factor (G-CSF; AX200; Filgrastim)
is a stroke drug candidate with excellent preclinical evidence for efficacy. A previous phase …
is a stroke drug candidate with excellent preclinical evidence for efficacy. A previous phase …
Granulocyte Colony-Stimulating Factor in Patients With Acute Ischemic Stroke: Results of the AX200 for Ischemic Stroke Trial.
EB Ringelstein, V Thijs, B Norrving… - Stroke: a journal of …, 2013 - lup.lub.lu.se
Granulocyte colony-stimulating factor (G-CSF; AX200; Filgrastim) is a stroke drug candidate
with excellent preclinical evidence for efficacy. A previous phase IIa dose-escalation study …
with excellent preclinical evidence for efficacy. A previous phase IIa dose-escalation study …
Major Clinical Trials
Stroke, 2013 - Am Heart Assoc
Background and Purpose—Granulocyte colony–stimulating factor (G-CSF; AX200;
Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy. A …
Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy. A …
Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial.
EB Ringelstein, V Thijs, B Norrving, A Chamorro… - Stroke, 2013 - europepmc.org
Background and purpose Granulocyte colony-stimulating factor (G-CSF; AX200; Filgrastim)
is a stroke drug candidate with excellent preclinical evidence for efficacy. A previous phase …
is a stroke drug candidate with excellent preclinical evidence for efficacy. A previous phase …
Granulocyte Colony-Stimulating Factor in Patients With Acute Ischemic Stroke: Results of the AX200 for Ischemic Stroke Trial.
EB Ringelstein, V Thijs, B Norrving… - Stroke: a journal of …, 2013 - portal.research.lu.se
Granulocyte colony-stimulating factor (G-CSF; AX200; Filgrastim) is a stroke drug candidate
with excellent preclinical evidence for efficacy. A previous phase IIa dose-escalation study …
with excellent preclinical evidence for efficacy. A previous phase IIa dose-escalation study …